查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997198

切片检查引导系统市场：2026-2032年全球市场预测（依影像技术、切片检查类型、引导系统、应用和最终用户划分）

Biopsy Guidance System Market by Imaging Technology, Biopsy Type, Guidance System, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，切片检查引导系统市场价值将达到 16.6 亿美元，到 2026 年将成长至 17.9 亿美元，到 2032 年将达到 27.8 亿美元，复合年增长率为 7.62%。

主要市场统计数据
基准年 2025 16.6亿美元
预计年份：2026年 17.9亿美元
预测年份 2032 27.8亿美元
复合年增长率 (%) 7.62%

对切片检查引导市场进行全面展望，为相关人员提出临床、技术、监管和营运要求框架。

在临床需求和技术成熟度的双重驱动下，切片检查引导生态系统正经历快速创新期。临床医师在追求更高诊断准确率的同时，力求最大限度地减少患者的不适感和手术相关风险，这使得先进的影像技术和引导平台的重要性日益凸显。同时，医疗设备製造商和解决方案供应商正致力于整合、互通性和工作流程最佳化，以缩短手术时间并提高可重复性。这些因素正在重塑医院、门诊和诊断机构的采购标准。

机器人技术、多模态成像和软体智慧的创新融合如何重新定义切片检查引导程序的准确性和临床价值。

随着机器人技术、先进影像技术和软体智慧的融合，切片检查引导领域正经历变革，其操作精度和临床可靠性也随之提升。机器人辅助技术正从概念验证阶段走向常规工作流程，即使在解剖结构复杂的病例中，也能实现可重复的操作路径和高度精确的目标定位。同时，电脑断层扫描（CT）和磁振造影（MRI）等影像技术不断提高软组织对比度和空间分辨率，超音波凭藉先进的二维、3D和多普勒功能而日益多样化，从而拓展了其在临床应用中的适用范围。

评估近期美国关税变化对指导体系中的采购、供应链韧性和产品架构的营运和策略影响。

美国近期关税政策的变化进一步增加了切片检查引导系统跨境采购和供应链规划的复杂性。关税调整影响范围广泛，涵盖从影像处理电子元件到精密机械组件的各个方面，导致最终成本发生变化，并促使跨国供应商重新评估筹资策略。为此，许多供应商正在探索近岸外包方案、实现供应商多元化，并调整库存策略以应对成本的快速波动。这些营运措施旨在维持利润率，同时确保向高优先临床客户供应产品。

深入了解将影像方式、临床应用、终端使用者环境、切片检查技术和引导平台连接起来的细分市场，从而形成可操作的商业化路径。

关键细分趋势凸显了临床需求与技术差异化的交汇点，为有针对性的投资和商业化策略提供了指南。基于影像技术，市场涵盖电脑断层扫描 (CT)、磁振造影(MRI)、立体定位系统、超音波和X光设备，其中超音波进一步细分为二维超音波、3D超音波和多普勒超音波。每种成像方式在组织对比度、可及性和手术应用方面都具有独特的优势，从而影响设备的整合优先顺序。基于应用领域，临床重点领域涵盖乳房、肾臟、肝臟、肺部、前列腺和甲状腺手术，每种应用都有其独特的影像、穿刺和切片检查处理要求，这些要求会影响产品设计和培训需求。

影响部署、伙伴关係和商业化策略的美洲、欧洲、中东、非洲和亚太地区的区域趋势和营运流程。

区域趋势影响技术的采用率、报销框架和伙伴关係生态系统，了解这些细微差别对于制定有效的市场进入和扩大策略至关重要。在美洲，需求模式受到不同的支付方环境和临床创新中心的影响，这些因素推动了先进导航平台的早期应用。采购决策通常受临床证据和医院系统优先事项的驱动，但门诊中心越来越倾向于寻求经济高效、高容量的解决方案。在欧洲、中东和非洲，不同的监管环境和基础设施成熟度导致了不同的技术采用曲线。集中式的三级医疗机构是先进技术的中心，而经济高效、可携的设备则更受偏远和资源匮乏地区的青睐。

那些优先考虑临床证据、互通生态系统、模组化产品策略以及为买家提供全面生命週期支援的公司的竞争优势。

切片检查引导领域的竞争格局主要围绕着那些成功将硬体可靠性、软体智慧和卓越服务整合为一个完整价值提案的公司。主要企业透过持续投资于临床证据、法规遵循和互通性来脱颖而出，从而促进与医院资讯系统和影像檔案库的整合。模组化产品生态系统——使医疗机构能够从手动引导过渡到机器人辅助引导併升级影像模组——正受到那些优先考虑未来适应性和总体拥有成本的买家的青睐。

领导企业可采取的策略重点，以协调产品开发、证据产生、供应链韧性和商业性差异化服务模式。

产业领导企业应优先推进一系列倡议，将市场资讯转化为永续的商业性优势和临床应用。首先，投资于能够使产品开发与特定治疗方式的性能要求和终端用户实际工作流程相契合、减少操作差异并支持临床医生快速掌握相关技术的解决方案。其次，针对乳癌、肝癌、肺癌、摄护腺癌、肾臟癌和甲状腺癌等关键适应症，建立强而有力的临床证据项目，以展现比较优势并支持有利的采购决策。第三，透过供应商多元化、评估近岸外包方案以及维持策略性库存来增强供应链韧性，从而降低关税和物流风险。

我们高度透明、以临床医生为中心的调查方法，结合与主要相关人员的对话、监管检验和情境分析，提供了切实可行的见解。

本研究结合了对临床医生、采购负责人和行业高管的访谈，以及对监管指南、临床文献和产品规格的广泛审查，以确保获得以临床医生为中心的可靠见解。资料收集强调跨职能观点，以捕捉临床工作流程、培训需求和采购决策标准。分析方法将质性主题分析与产品特性和服务方案的结构化比较评估结合。这种方法有意优先考虑三角验证，以协调不同相关人员的观点，并为商业化和临床部署提供可操作的见解。

整合临床、技术和商业性需求，为切片检查引导系统的广泛应用和市场主导制定路径。

总之，切片检查引导领域正从渐进式改进迈向一体化创新阶段，影像技术、机器人辅助和智慧软体的进步正在融合，重新定义该手术的标准。临床上对更高精度和更轻患者负担的需求推动了技术的普及，而采购决策也越来越依赖临床价值、互通性和服务连续性方面的证据。定价和供应链趋势进一步增加了策略复杂性，迫使製造商和采购商优先考虑韧性和灵活性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：切片检查引导系统市场的应用

  • 电脑断层扫描
  • 磁振造影
  • 本土化
  • 超音波
    • 二维超音波
    • 三维超音波
    • 多普勒超音波
  • X射线

第九章：依切片检查类型分類的切片检查引导系统市场

  • 核心针穿刺切片
    • 弹簧型
    • 吸力辅助型
  • 细针穿刺切片检查

第十章：切片检查引导系统市场指南（依系统划分）

  • 手动的
  • 机器人辅助

第十一章：切片检查引导系统市场：按应用领域划分

  • 胸部
  • 肾
  • 肝
  • 肺
  • 摄护腺
  • 甲状腺

第十二章：切片检查引导系统市场：依最终用户划分

  • 门诊手术中心
  • 诊断影像中心
  • 医院
    • 私立医院
    • 公立医院
  • 门诊部

第十三章：切片检查引导系统市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：切片检查引导系统市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：切片检查引导系统市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国切片检查引导系统市场

第十七章：中国切片检查引导系统市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Argon Medical Devices, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Cook Medical, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Olympus Corporation
  • Siemens Healthineers AG
  • Stryker Corporation
Product Code: MRR-C271879142B5

The Biopsy Guidance System Market was valued at USD 1.66 billion in 2025 and is projected to grow to USD 1.79 billion in 2026, with a CAGR of 7.62%, reaching USD 2.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.66 billion
Estimated Year [2026] USD 1.79 billion
Forecast Year [2032] USD 2.78 billion
CAGR (%) 7.62%

A definitive orientation to the biopsy guidance landscape that frames clinical drivers, technology enablers, regulatory pressures, and operational imperatives for stakeholders

The biopsy guidance ecosystem has entered a period of accelerated innovation driven by converging clinical imperatives and technology maturation. Clinicians seek higher diagnostic accuracy while minimizing patient discomfort and procedural risk, which has elevated the importance of advanced imaging modalities and guidance platforms. Simultaneously, device manufacturers and solution providers are focusing on integration, interoperability, and workflow efficiencies that reduce procedure time and enhance reproducibility. These forces are reshaping procurement criteria across hospitals, ambulatory centers, and diagnostic facilities.

Against this backdrop, stakeholders must navigate a complex interplay of clinical adoption pathways, regulatory expectations, and reimbursement dynamics. Evidence generation that demonstrates comparative clinical value increasingly influences adoption decisions, and payers are scrutinizing procedure outcomes and cost-effectiveness. As a result, product development roadmaps prioritize ease of use, reduced procedural variability, and compatibility with existing imaging infrastructure. This introduction frames the broader context for subsequent analysis by highlighting the clinical drivers, technology enablers, and operational priorities that are defining the current phase of market evolution.

How converging innovations in robotics, multimodal imaging, and software intelligence are redefining procedural precision and clinical value in biopsy guidance

The landscape for biopsy guidance is experiencing transformative shifts as robotics, imaging refinement, and software intelligence converge to elevate procedural precision and clinical confidence. Robotic assistance is moving beyond proof of concept toward integration in routine workflows, enabling reproducible trajectories and enhanced targeting in anatomically challenging cases. Concurrently, imaging technologies such as computed tomography and magnetic resonance imaging are delivering finer soft tissue contrast and spatial resolution, while ultrasound platforms are diversifying into advanced two dimensional, three dimensional, and Doppler capabilities that expand point-of-care applicability.

Moreover, the rise of real-time navigation systems and image fusion is smoothing the path for multimodal approaches that combine the strengths of each imaging modality. Software-driven decision support, including lesion characterization and trajectory planning, is becoming an expected component of comprehensive solutions. Taken together, these shifts are recalibrating value propositions: purchasers increasingly reward systems that reduce repeat procedures, shorten learning curves, and integrate with electronic medical records. As adoption accelerates, suppliers who prioritize validated clinical outcomes and interoperable ecosystems will be best positioned to capture sustained preference across varied clinical settings.

Assessing the operational and strategic consequences of recent United States tariff shifts on procurement, supply chain resilience, and product architecture for guidance systems

Recent tariff developments in the United States have introduced increased complexity into cross-border procurement and supply chain planning for biopsy guidance systems. Tariff adjustments affect components ranging from imaging electronics to precision mechanical assemblies, altering landed costs and prompting multinational vendors to reassess sourcing strategies. In response, many suppliers are evaluating nearshoring options, diversifying supplier bases, and adjusting inventory policies to buffer against sudden cost fluctuations. These operational moves aim to preserve margin while maintaining product availability for high-priority clinical customers.

Beyond direct cost implications, tariff-driven shifts can influence product architecture and aftersales economics. Manufacturers may redesign modules to rely on domestically sourced subcomponents or alter assembly footprints to mitigate exposure. Such redesign efforts have downstream effects on regulatory documentation and validation timelines, necessitating proactive change management. From a buyer perspective, procurement officers need to account for longer lead times and potential requalification activities when switching suppliers. Overall, tariffs are accelerating strategic supply chain resilience planning and making commercial agility a core competency for stakeholders across the value chain.

Segmentation insights that map imaging modalities, clinical applications, end-user settings, biopsy techniques, and guidance platforms into actionable commercialization pathways

Key segmentation dynamics reveal where clinical demand and technological differentiation intersect, offering guidance for targeted investment and commercialization strategies. Based on imaging technology, the market spans computed tomography, magnetic resonance imaging, stereotactic systems, ultrasound, and X ray equipment, with ultrasound further differentiated into two dimensional ultrasound, three dimensional ultrasound, and Doppler ultrasound; each modality carries distinct strengths for tissue contrast, accessibility, and procedural context, shaping device integration priorities. Based on application, clinical focus areas encompass breast, kidney, liver, lung, prostate, and thyroid procedures, and each application imposes unique imaging, needle access, and biopsy handling requirements that influence product design and training needs.

End-user segmentation identifies ambulatory surgical centers, diagnostic imaging centers, hospitals, and outpatient clinics as primary care settings, with hospitals further split into private and public institutions; these distinctions matter because procurement cycles, capital availability, and clinical governance vary substantially across settings. Based on biopsy type, practices differentiate between core needle biopsy and fine needle aspiration, while core needle approaches subdivide into spring loaded and vacuum assisted mechanisms; the choice among these reflects tradeoffs between tissue yield, procedural invasiveness, and pathology processing workflows. Finally, guidance system preferences fall across manual and robotic assisted platforms, and adoption trajectories depend on perceived gains in accuracy, workflow disruption, and clinician proficiency. Collectively, these segmentation lenses highlight opportunities for product tailoring, differentiated clinical evidence generation, and customized service models that address the specific needs of each modality, application, end user, and procedural technique.

Regional dynamics and operational pathways across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, partnerships, and commercialization strategies

Regional dynamics shape adoption speed, reimbursement frameworks, and partnership ecosystems, and understanding these nuances is essential for effective market entry and scale strategies. In the Americas, demand patterns are influenced by heterogeneous payer landscapes and concentrated centers of clinical innovation that drive early adoption of advanced guidance platforms; procurement decisions are often shaped by clinical evidence and hospital system priorities, while ambulatory centers increasingly seek cost-effective, high-throughput solutions. In Europe, Middle East & Africa, regulatory diversity and variable infrastructure maturity lead to differentiated adoption curves where centralized tertiary hospitals frequently act as hubs for sophisticated technologies, while remote and resource-constrained settings prioritize cost-effective, portable modalities.

Across Asia-Pacific, a mix of rapidly modernizing healthcare systems and large patient volumes creates both scale opportunities and the need for localized commercialization strategies; demand often favors adaptable solutions that align with diverse clinical workflows and varying levels of imaging infrastructure. Regional talent pools, local manufacturing incentives, and distribution partnerships further influence how companies deploy training, service models, and aftermarket support. By aligning product value propositions with regional clinical imperatives and procurement realities, stakeholders can optimize market entry sequencing and partnership selection to maximize clinical impact and commercial uptake.

Competitive company dynamics that reward clinical evidence, interoperable ecosystems, modular product strategies, and comprehensive lifecycle support for buyers

Competitive dynamics within the biopsy guidance arena center on firms that successfully blend hardware reliability, software intelligence, and service excellence into a coherent value proposition. Leading companies differentiate through sustained investment in clinical evidence, regulatory stewardship, and interoperability that eases integration with hospital information systems and imaging archives. Product ecosystems that offer modularity-allowing facilities to scale from manual to robotic assisted guidance or to upgrade imaging modules-tend to resonate with purchasers who prioritize future-proofing and total cost of ownership.

Additionally, companies that provide comprehensive training, remote support, and predictive maintenance capabilities can reduce procedural variability and enhance customer retention. Strategic partnerships between device makers, software vendors, and clinical centers generate real-world evidence and foster user communities that accelerate best-practice dissemination. New entrants face high expectations around clinical validation and service continuity, while incumbents must guard against commoditization by continuously enhancing user experience and demonstrating measurable outcomes. Hence, competitive advantage increasingly derives from a combination of clinical credibility, integration capability, and aftersales service depth.

Actionable strategic priorities for leaders to align product development, evidence generation, supply chain resilience, and commercially differentiated service models

Industry leaders should pursue a prioritized set of actions that translate market intelligence into sustained commercial advantage and clinical adoption. First, align product development with modality-specific performance requirements and end-user workflow realities, investing in solutions that reduce procedural variability and support rapid clinician proficiency. Second, build robust clinical evidence programs across key applications such as breast, liver, lung, prostate, kidney, and thyroid to validate comparative benefits and support favorable procurement decisions. Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring options, and maintaining strategic inventories to mitigate tariff and logistics risks.

In parallel, cultivate interoperable software platforms that facilitate image fusion, trajectory planning, and seamless integration with electronic health records to lower adoption barriers. Develop tailored commercial models that address the distinct needs of hospitals, ambulatory surgical centers, diagnostic imaging centers, and outpatient clinics, and offer flexible financing or bundled service agreements to ease capital constraints. Finally, invest in training, remote support, and predictive maintenance to reduce downtime and enhance clinician confidence. Executed coherently, these actions will improve clinical outcomes, accelerate adoption, and strengthen long-term partnerships with health systems and diagnostic providers.

A transparent and clinician centered research methodology combining primary stakeholder engagement, regulatory validation, and scenario analysis to underpin practical insights

This research synthesizes primary interviews with clinicians, procurement professionals, and industry executives alongside an extensive review of regulatory guidance, clinical literature, and product specifications to ensure robust, clinician-centric insights. Data collection emphasized cross-functional perspectives to capture clinical workflows, training requirements, and procurement decision criteria, and analytic methods integrated qualitative thematic analysis with structured comparative assessments of product capabilities and service offerings. The approach intentionally prioritized triangulation to reconcile divergent stakeholder perspectives and to surface pragmatic implications for commercialization and clinical adoption.

Quality assurance measures included validation of technical claims against regulatory filings and peer-reviewed clinical studies, as well as iterative review cycles with domain experts to refine interpretations. Where applicable, sensitivity testing was applied to supply chain and operational scenarios to assess resilience under different tariff and logistics conditions. The methodology is designed to be transparent and reproducible, providing stakeholders with confidence in the findings and enabling targeted follow-up analyses to address specific clinical or commercial questions.

Synthesis of clinical, technological, and commercial imperatives that define the pathway to wider adoption and leadership in biopsy guidance systems

In conclusion, the biopsy guidance field is transitioning from incremental improvements toward a phase of integrative innovation where imaging evolution, robotic assistance, and smart software converge to redefine procedural standards. Clinical demand for higher accuracy and reduced patient burden is catalyzing adoption, while procurement choices are increasingly shaped by evidence of clinical value, interoperability, and service continuity. Tariff and supply chain dynamics add another layer of strategic complexity, prompting manufacturers and purchasers to prioritize resilience and agility.

For stakeholders, the path forward involves aligning technology development with specific application needs, investing in rigorous clinical validation, and delivering tailored commercial and service models that reflect the realities of diverse end users and regions. Companies that successfully marry clinical credibility with operational reliability and flexible deployment models will lead adoption and create durable competitive positions. The industry is poised for impactful advances, and timely strategic choices will determine who captures leadership as technologies move from specialized settings into mainstream clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Guidance System Market, by Imaging Technology

  • 8.1. Computed Tomography
  • 8.2. Magnetic Resonance Imaging
  • 8.3. Stereotactic
  • 8.4. Ultrasound
    • 8.4.1. 2D Ultrasound
    • 8.4.2. 3D Ultrasound
    • 8.4.3. Doppler Ultrasound
  • 8.5. X Ray

9. Biopsy Guidance System Market, by Biopsy Type

  • 9.1. Core Needle Biopsy
    • 9.1.1. Spring Loaded
    • 9.1.2. Vacuum Assisted
  • 9.2. Fine Needle Aspiration

10. Biopsy Guidance System Market, by Guidance System

  • 10.1. Manual
  • 10.2. Robotic Assisted

11. Biopsy Guidance System Market, by Application

  • 11.1. Breast
  • 11.2. Kidney
  • 11.3. Liver
  • 11.4. Lung
  • 11.5. Prostate
  • 11.6. Thyroid

12. Biopsy Guidance System Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals
  • 12.4. Outpatient Clinics

13. Biopsy Guidance System Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopsy Guidance System Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopsy Guidance System Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopsy Guidance System Market

17. China Biopsy Guidance System Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Argon Medical Devices, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Canon Medical Systems Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. Cook Medical, Inc.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. GE HealthCare Technologies Inc.
  • 18.14. Hologic, Inc.
  • 18.15. Koninklijke Philips N.V.
  • 18.16. Medtronic plc
  • 18.17. Olympus Corporation
  • 18.18. Siemens Healthineers AG
  • 18.19. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 174. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 177. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 201. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 210. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)